Dynavax Technologies (DVAX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

DVAX Dynavax Technologies

Watchlist

12.820
+0.130+1.02%

Close Feb 14 16:00 ET

12.820
0.0000.00%

Post 20:01 ET

1.69BMarket Cap85.47P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Week Ahead: BABA, XYZ, BIDU, WMT, RIVN and More
Seeking Alpha17minutes ago
Earnings Preview: DVAX to Report Financial Results Post-market on February 20
Moomoo NewsFeb 14 20:00 ET
The demand outlook for shingles and hepatitis B vaccines is uncertain, and Goldman Sachs is bearish on Dynavax Technologies (DVAX.US).
Goldman Sachs has downgraded Dynavax Technologies (DVAX.US) from "neutral" to "Sell" and has lowered the Target Price from $15 to $12.
Zhitong FinanceFeb 11 22:45 ET
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
BenzingaFeb 11 15:11 ET
This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
BenzingaFeb 11 07:07 ET
Goldman Sachs Downgrades Dynavax Technologies(DVAX.US) to Sell Rating, Cuts Target Price to $12
Moomoo NewsFeb 11 05:32 ET · Ratings

Comments

Jaguar8

Jan 13 08:14

NEWS

$Dynavax Technologies (DVAX.US)$
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
HEPLISAV-B revenue grew 26% YoY to $268 million in 2024
Q4 2024 revenue increased 39% YoY to $71 million
Strong cash position of $714 million
New $30 million DoD contract for plague vaccine development
Expected market expansion to $900 million by 2030 with 60% target market share
Negative
None.

Trytosaveabit

Jan 13 08:11

News

$Dynavax Technologies (DVAX.US)$ Dynavax Awarded $30M Contract With U.S. Department of Defense >DVAX
Dow Jones· 3 mins ago

Jaguar8

Nov 15, 2024 12:54

NEWS

$Dynavax Technologies (DVAX.US)$
Dynavax Technologies Down Over 7%, On Track for Largest Percent Decrease Since August 2022 -- Data Talk
Dow Jones· 2 mins ago2mins
Dynavax Technologies Corporation ( DVAX ) is currently at $12.42, down $0.97 or 7.21%
--Would be lowest close since Nov. 7, 2024, when it closed at $12.02
--On pace for largest percent decrease since Aug. 17, 2022, when it fell 10.39%
--Currently down three of the past four days
--Currently down two consecutive days; down 8.1% ov...

Jaguar8

Nov 7, 2024 15:07

NEWS

$Dynavax Technologies (DVAX.US)$
Dynavax Announces $200 Million Share Repurchase Program
Dynavax (DVAX) reported strong Q3 2024 financial results, with HEPLISAV-Bachieving record quarterly net product revenue of $79.3 million, up 27% year-over-year. The company's total revenues reached $80.6 million, a 16% increase from Q3 2023. HEPLISAV-B's U.S. market share grew to 44%, with particularly strong performance in retail pharmacy (55%) and IDN segments (56%). The company expects the hepatitis B...

Meltyy

May 20, 2024 21:57

🔔 FDA PDUFA Update…

📣 2 PDUFAs left in May!
🗓️ Last week’s PDUFAs:
$Amgen (AMGN.US)$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb (BMY.US)$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies (DVAX.US)$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S (ASND.US)$ : Review extended to 8/14/24 🤔
⇒ YORV...

Trending Stocks

Symbol Mini Chart % Chg

Unlock the Full List